The US Food and Drug Administration (FDA) has finalized two guidances for sponsors and investigators regarding adverse event reporting for drugs, biologics, and medical devices in clinical studies.
The Draft Guidance provides an extensive overview of sponsors’ safety reporting requirements. However, in addition to general IND safety reporting requirements, a major focus is updated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results